User:Mr. Ibrahem/Colchicine
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Colcrys, Mitigare, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682711 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 45% |
| Protein binding | 35-44% |
| Metabolism | Metabolism, partly by CYP3A4 |
| Elimination half-life | 26.6-31.2 hours |
| Excretion | Faeces (65%) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H25NO6 |
| Molar mass | 399.437 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Colchicine is a medication used to treat gout and Behçet's disease.[2][3][4] In gout, it is less preferred to NSAIDs or steroids.[3] Other uses include the prevention of pericarditis and familial Mediterranean fever.[3][5] It is taken by mouth.[3]
Common side effects include gastrointestinal upset, particularly at high doses.[6] Severe side effects may include low blood cells and rhabdomyolysis.[3] Safety of use during pregnancy is unclear while use during breastfeeding appears safe.[3][7] Excessive doses may result in death.[3] Colchicine works by decreasing inflammation via multiple mechanisms.[8]
Colchicine, in the form of the autumn crocus, has been used as early as 1500 BC to treat joint swelling.[9] It was approved for medical use in the United States in 1961.[10] It is available as a generic medication in the United Kingdom, where a month's supply costs the NHS about £7.27 as of 2019.[7] In the United States, the wholesale cost of this amount is about US$252.20.[11] In 2017, it was the 201st most commonly prescribed medication in the United States, with more than two million prescriptions.[12][13]
References[edit]
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 9 September 2020.
- ^ Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O'Hanlon CE, Tariq A, et al. (January 2017). "Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline". Annals of Internal Medicine. 166 (1): 37–51. doi:10.7326/M16-0461. PMID 27802478.
- ^ a b c d e f g "Colchicine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 27 March 2019.
- ^ Schachner, Lawrence A.; Hansen, Ronald C. (2011). Pediatric Dermatology E-Book. Elsevier Health Sciences. p. 177. ISBN 9780723436652.
- ^ Hutchison, Stuart J. (2009). Pericardial Diseases: Clinical Diagnostic Imaging Atlas with DVD. Elsevier Health Sciences. p. 58. ISBN 9781416052746.
- ^ "Colchicine for acute gout: updated information about dosing and drug interactions". National Prescribing Service, Australia. 14 May 2010. Archived from the original on 30 June 2012. Retrieved 14 May 2010.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 1085–1086. ISBN 9780857113382.
- ^ Dalbeth N, Lauterio TJ, Wolfe HR (October 2014). "Mechanism of action of colchicine in the treatment of gout". Clinical Therapeutics. 36 (10): 1465–79. doi:10.1016/j.clinthera.2014.07.017. PMID 25151572.
- ^ Wall, Wilson John (2015). The Search for Human Chromosomes: A History of Discovery. Springer. p. 88. ISBN 9783319263366.
- ^ "Colchicine capsule". DailyMed. Retrieved 27 March 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Colchicine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.